Change over period: —
NSE · LALPATHLAB
LALPATHLAB
-3.2% from the 52-week high · +50.3% above the low
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. The company is headquartered in Gurgaon, Haryana and currently employs 4,048 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.
The short version. LALPATHLAB reported revenue of ₹874 crore for Sep 2026, up 19.6% from a year earlier. Net profit was ₹192 crore (up 27.2% year on year). Return on equity was 20.1% in Mar 2026. Promoter holding was 52.93% in Sep 2026, down 0.98 points over 8 quarters.
1 · The price
How has the stock traded?
LALPATHLAB trades 3.2% below its 52-week high and 50.3% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹874 cr.
Sep 2026 net profit of ₹192 cr.
1.4 pts higher than a year earlier.
Revenue compounded at 11.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 874 | 798 | 703 | 660 | 731 | 670 | 603 | 597 |
| Net profit | 192 | 170 | 131 | 90 | 151 | 132 | 155 | 97 |
| Net margin % | 22.0 | 21.2 | 18.7 | 13.7 | 20.6 | 19.8 | 25.7 | 16.2 |
| EPS (₹) | 11.45 | 10.11 | 7.84 | 5.4 | 8.99 | 7.9 | 9.26 | 5.78 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2763 | 2461 | 2227 | 2017 | 2087 | 1581 | 1330 | 1203 |
| Net profit | 505 | 487 | 358 | 239 | 345 | 292 | 226 | 199 |
| Net margin % | 18.3 | 19.8 | 16.1 | 11.8 | 16.5 | 18.4 | 17.0 | 16.6 |
| EPS (₹) | 30.13 | 29.14 | 21.42 | 14.33 | 20.69 | 17.49 | 13.55 | 11.95 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 20.1% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 20.1 | 22.4 | 19.3 | 14.3 |
| Return on capital % | 25.7 | 28.0 | 26.9 | 19.9 |
| EBITDA margin % | 29.8 | 30.9 | 29.5 | 25.8 |
| Net margin % | 17.6 | 19.1 | 15.6 | 11.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 11.6% | 11.9% |
| Profit CAGR | 28.3% | 11.6% |
4 · The owners
Who holds it, and are they adding?
Down 0.98 pts over 8 quarters.
Down 8.09 pts over 8 quarters.
Up 8.41 pts over 8 quarters.
+50 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.91 | 53.91 | 53.79 | 53.21 | 53.21 | 53.21 | 53.19 | 52.93 | -0.98 |
| FII | 26.82 | 23.91 | 21.68 | 21.86 | 20.29 | 17.18 | 17.36 | 18.73 | -8.09 |
| DII | 13.17 | 16.08 | 17.91 | 18.49 | 19.21 | 21.38 | 21.59 | 21.58 | +8.41 |
| Public | 5.82 | 5.84 | 6.23 | 6.07 | 6.94 | 7.87 | 7.47 | 6.35 | +0.53 |
Mutual fund holdings · Oct 2026
169 schemes hold this stock
119 the month before.
- ICICI Prudential Life Cycle Fund 20318.06% of NAV
- PGIM INDIA HEALTHCARE FUND4.34% of NAV
- NJ ELSS Tax Saver Fund4.11% of NAV
- NJ Flexi Cap Fund4.09% of NAV
- ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND3.9% of NAV
- Capitalmind Flexi Cap Fund3.15% of NAV
- DSP Nifty Smallcap250 Quality 50 Index Fund3.14% of NAV
- the Quantum Ethical Fund3.14% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for LALPATHLAB are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about LALPATHLAB
What is the LALPATHLAB share price?
LALPATHLAB (LALPATHLAB) last closed at ₹1,968.50, up 0.16% on the day. Its 52-week range is ₹1,307.60 to ₹2,029.40.
What is the market cap of LALPATHLAB?
LALPATHLAB has a market capitalisation of about ₹32,863 crore. Its price-to-earnings ratio is 56.7.
How are LALPATHLAB's latest results?
LALPATHLAB reported revenue of ₹874 crore for Sep 2026, up 19.6% from a year earlier. Net profit was ₹192 crore (up 27.2% year on year). Return on equity was 20.1% in Mar 2026. Promoter holding was 52.93% in Sep 2026, down 0.98 points over 8 quarters.
Who owns LALPATHLAB?
As of Sep 2026, shareholding was: Promoter 52.93%, FII 18.73%, DII 21.58%, Public 6.35%.
How many mutual funds hold LALPATHLAB?
169 mutual fund schemes held LALPATHLAB in October 2026. That compares with 119 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 25 Jun 2026 · Final Dividend - Rs. 4
- 05 Feb 2026 · Interim Dividend - Rs. 3.5
- 19 Dec 2025 · Bonus issue 1:1
- 07 Nov 2025 · Interim Dividend - Rs. 7
- 06 Aug 2025 · Interim Dividend - Rs. 6
- 06 Jun 2025 · Final Dividend - Rs. 6
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.